Pay in 4 interest-free payments of $6.52 Learn more
Ships within 48 hours · Estimated delivery Sep 9 - Sep 14
90% of the 38 million type 2 diabetics in the US are overweight
In preliminary results of OASIS 1, a recent 68-week, phase 3a clinical trial that compared once-daily oral semaglutide with placebo in adults with obesity or overweight with one or more underlying comorbidities, the average weight loss from baseline was 15.1% in the semaglutide group and 2.4% in the placebo group
Potential side effects may include nausea, vomiting, diarrhea, abdominal discomfort, and reduced appetite
Minority populations are particularly affected, with half or more of newly diagnosed cases of type 2 diabetes in childhood and adolescence occurring in Hispanic, non-Hispanic Black, Asian/Pacific Islander and American Indian populations [268]
About 21.7%, one of the lowest among major US cities
Mean T 1/2 was 138.4 minutes (95% CI 74.5202.3) for GLP-1 RA vs 95.0 minutes (95% CI 54.9135.0) for placebo, with a pooled mean difference of 36.0 minutes (95% CI 17.055.0, P 0.05)
US$ 20.39
US$ 23.34
US$ 28.33
US$ 25.99
US$ 21.83
